Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax

The treatment of acute myeloid leukemia (AML) is developing towards “targeted therapy”, which faces challenges such as low sensitivity and drug resistance. Therefore, targeted drugs need to be used in combination with other drugs to overcome clinical problems. AML cells and animal models were used t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Experimental cell research 2022-08, Vol.417 (2), p.113192-113192, Article 113192
Hauptverfasser:	Liu, Hongcai, Hussain, Zubair, Xie, Qingqing, Yan, Xueying, Zeng, Chenxing, Zhou, Gan, Cao, Shan
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia (AML) Dactolisib (BEZ235) Inherent resistance PI3K/AKT/mTOR pathway Synergistic anti-tumor effect Venetoclax (ABT199)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!